Tirzepatide: The Dual GIP/GLP-1 Peptide That Outperforms Semaglutide
Tirzepatide is the first dual-agonist approved for weight loss, hitting both GIP and GLP-1. It outperforms semaglutide by about 6 percentage points in head-to-head trials.
Tirzepatide (Mounjaro, Zepbound) is the first dual GIP and GLP-1 receptor agonist on the market. By hitting both incretin pathways, it produces ~22% body weight loss at 15 mg weekly in 72-week trials — the largest effect ever recorded for a non-surgical obesity treatment.
Why Dual Agonism Matters
GLP-1 alone slows gastric emptying and suppresses appetite. GIP appears to improve insulin sensitivity, increase energy expenditure, and — counterintuitively — help offset the nausea that pure GLP-1 agonists cause. The combination produces more weight loss with comparable or better tolerability.
Titration Schedule
Standard ramp is 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg, increasing every 4 weeks. Many users plateau at 7.5 or 10 mg with excellent results; pushing to 15 mg is reserved for users with more weight to lose or insulin resistance.
Compared to Semaglutide
Head-to-head SURPASS-2 data showed roughly 6 percentage points more weight loss at equivalent timepoints, with similar GI side effect profiles. Cost and access often drive the choice between the two more than efficacy differences.
Reference page
Reconstitution chart, dose calculator, and storage notes for this peptide.
Open the reference cardFAQ
- Can you switch from semaglutide to tirzepatide?
- Yes — most protocols restart titration from 2.5 mg rather than dose-matching, because the GIP component requires its own acclimation window.